They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Merck & Co. Inc. (NYSE: MRK) resulting from allegations ...

Analysts covering Merck predict earnings growth of 17.6% in 2025 and an additional 10.4% increase in 2026. With shares currently trading at seven times forward 2025 earnings, Merck appears to be an ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

As more cancers are being linked to the human papillomavirus (HPV), including cancers showing up in younger-than-average patients, a local doctor is promoting the use of the HPV vaccine, which is ...

MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has ...

Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

US pharma giant Merck & Co opened Tuesday’s trading 10% lower after announcing its annual and fourth quarter financial ...